Promising, inexpensive generic drugs may never receive large-scale testing as anti-aging treatments—not because the science is weak, but because the pharmaceutical regulatory system rewards patentable products over affordable public-health solutions. Metformin and rapamycin have shown potential in animal research to influence aging-related biological processes.
Yet definitive human trials remain limited. The central obstacle is financial: rigorous Phase 3 trials can cost hundreds of millions of dollars, while manufacturers have little incentive to fund studies of off-patent drugs that competitors could immediately sell at low prices.
That market failure becomes a regulatory failure when government agencies rely primarily on industry-sponsored trials to determine which treatments receive approved indications. Rather than independently testing promising generics, the system waits for companies to finance the evidence regulators demand. The relationship is further complicated by the FDA’s dependence on manufacturer-paid user fees.
A Government Accountability Office report found that industry fees had grown to cover 61.5% of FDA drug-review costs by fiscal year 2010. Current law continues to authorize these payments in exchange for agency performance commitments.
This does not prove regulators are taking direct orders from pharmaceutical companies. It does reveal structural capture as public rules, research priorities and approval pathways are aligned with the business models of the industry being regulated. In other words, Big Pharma is running the show.
Independent projects such as the proposed TAME metformin trial and a federally funded rapamycin study are attempting to fill the gap. Our health system should investigate treatments according to potential benefit—not patent profitability. RFK Jr. is trying to return our country back to a system where the vulnerable are not harmed for Big Pharma’s profit models.
